Stockreport

European Commission Grants Marketing Authorization for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection

Gilead Sciences, Inc.  (GILD) 
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
PDF – In Clinical Trials, Biktarvy Demonstrated High Efficacy and Zero Resistance Through 48 Weeks – FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead [Read more]